Tumor Biology

, Volume 36, Issue 10, pp 7439–7447 | Cite as

Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma

Research Article

Abstract

Previous studies have identified a number of microRNAs (miRNAs) that were aberrantly expressed in hepatocellular carcinoma (HCC) tissues. Nevertheless, their diagnostic and prognostic value in serum has not been fully evaluated. Herein, the levels of five serum miRNAs, namely, miR-182, miR-331-3p, miR-197, miR-492, and miR-581, were detected in 103 HCC patients, 95 benign liver diseases, and 40 healthy controls using real-time PCR technique. The results showed that, compared with benign liver diseases and healthy controls, the levels of serum miR-182 and miR-331-3p were significantly increased in HCC patients, both P < 0.001. Area under the receiver–operating characteristic (ROC) curves for serum miR-182 and miR-331-3p were 0.911 (95 % CI, 0.863–0.947) and 0.890 (95 % CI, 0.838–0.930), the sensitivity were 78.6 and 79.61 %, and the specificity were 91.58 and 86.32 %, respectively. Moreover, the combination of serum miR-182, miR-331-3p, and alpha-fetoprotein (AFP) can markedly increase the differential diagnostic value of benign and malignant liver diseases, especially better than serum AFP alone, P < 0.05. Serum miR-182 was positively correlated with serum AFP (P = 0.001), tumor size (P = 0.013), and TNM classification of malignant tumors (TNM) stage (P = 0.003); however, only TNM stage was demonstrated a significant correlation with serum miR-331-3p (P = 0.006). In addition, Kaplan–Meier survival curve, together with univariate and multivariate Cox proportional hazard analyses, further disclosed that serum miR-182 and miR-331-3p were associated with postoperative survival of HCC patients, and both of them were regarded to be independent prognostic factors for patients with HCC. Taken together, our present study indicates that serum miR-182 and miR-331-3p, upregulated in HCC, can provide positive diagnostic and prognostic values for HCC.

Keywords

Hepatocellular carcinoma MicroRNA-182 MicroRNA-331-3p Alpha-fetoprotein Diagnosis Prognosis 

References

  1. 1.
    Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844–55.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Xu WJ, Guo BL, Han YG, Shi L, Ma WS. Diagnostic value of alpha- fetoprotein-L3 and Golgi protein 73 in hepatocellular carcinomas with low AFP levels. Tumour Biol. 2014;35(12):12069–74.CrossRefPubMedGoogle Scholar
  3. 3.
    Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta. 2008;395(1–2):19–26.CrossRefPubMedGoogle Scholar
  4. 4.
    Park H, Park JY. Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma. Biomed Res Int. 2013;2013:310427.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Giannini EG, Sammito G, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, et al. Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use. Cancer. 2014;120(14):2150–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Han LL, Lv Y, Guo H, Ruan ZP, Nan KJ. Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy. World J Gastroenterol. 2014;20:10249–61.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol. 2014;20:4115–27.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Tutar L, Tutar E, Tutar Y. MicroRNAs and cancer; an overview. Curr Pharm Biotechnol. 2014;15:430–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Berger F, Reiser MF. Micro-RNAs as potential new molecular biomarkers in oncology: have they reached relevance for the clinical imaging sciences? Theranostics. 2013;3:943–52.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Li B, Huang P, Qiu J, Liao Y, Hong J, Yuan Y. MicroRNA-130a is down- regulated in hepatocellular carcinoma and associates with poor prognosis. Med Oncol. 2014;31:230.CrossRefPubMedGoogle Scholar
  11. 11.
    Chen P, Zhao X, Ma L. Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma. Mol Cell Biochem. 2013;383:49–58.CrossRefPubMedGoogle Scholar
  12. 12.
    Su ZX, Zhao J, Rong ZH, Geng WM, Wu YG, Qin CK. Upregulation of microRNA-25 associates with prognosis in hepatocellular carcinoma. Diagn Pathol. 2014;9:47.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Gu H, Guo X, Zou L, Zhu H, Zhang J. Upregulation of microRNA-372 associates with tumor progression and prognosis in hepatocellular carcinoma. Mol Cell Biochem. 2013;375:23–30.PubMedGoogle Scholar
  14. 14.
    Wang J, Zhang KY, Liu SM, Sen S. Tumor-associated circulating microRNAs as biomarkers of cancer. Molecules. 2014;19:1912–38.CrossRefPubMedGoogle Scholar
  15. 15.
    Meng FL, Wang W, Jia WD. Diagnostic and prognostic significance of serum miR-24-3p in HBV-related hepatocellular carcinoma. Med Oncol. 2014;31:177.CrossRefPubMedGoogle Scholar
  16. 16.
    Zhang ZQ, Meng H, Wang N, Liang LN, Liu LN, Lu SM, et al. Serum microRNA 143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma. Diagn Pathol. 2014;9:135.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Koberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J, et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer. 2013;49:3442–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Zheng H, Liu JY, Song FJ, Chen KX. Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer. Cancer Biol Med. 2013;10:123–30.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Yang Y, Gu X, Zhou M, Xiang J, Chen Z. Serum microRNAs: a new diagnostic method for colorectal cancer. Biomed Rep. 2013;1:495–8.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Yang MH, Yu J, Jiang DM, Li WL, Wang S, Ding YQ. microRNA-182 targets special AT-rich sequence-binding protein 2 to promote colorectal cancer proliferation and metastasis. J Transl Med. 2014;12:109.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Lei R, Tang J, Zhuang X, Deng R, Li G, Yu J, et al. Suppression of MIM by microRNA-182 activates RhoA and promotes breast cancer metastasis. Oncogene. 2014;33:1287–96.CrossRefPubMedGoogle Scholar
  22. 22.
    Zhu H, Fang J, Zhang J, Zhao Z, Liu L, Wang J, et al. miR-182 targets CHL1 and controls tumor growth and invasion in papillary thyroid carcinoma. Biochem Biophys Res Commun. 2014;450:857–62.CrossRefPubMedGoogle Scholar
  23. 23.
    Wang J, Li J, Shen J, Wang C, Yang L, Zhang X. MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma. BMC Cancer. 2012;12:227.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Qin J, Luo M, Qian H, Chen W. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1. Gene. 2014;538:342–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Epis MR, Giles KM, Kalinowski FC, Barker A, Cohen RJ, Leedman PJ. Regulation of expression of deoxyhypusine hydroxylase (DOHH), the enzyme that catalyzes the activation of eIF5A, by miR-331-3p and miR-642-5p in prostate cancer cells. J Biol Chem. 2012;287:35251–9.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Guo X, Guo L, Ji J, Zhang J, Zhang J, Chen X, et al. miRNA-331-3p directly targets E2F1 and induces growth arrest in human gastric cancer. Biochem Biophys Res Commun. 2010;398:1–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Epis MR, Giles KM, Candy PA, Webster RJ, Leedman PJ. miR-331-3p regulates expression of neuropilin-2 in glioblastoma. J Neurooncol. 2014;116:67–75.CrossRefPubMedGoogle Scholar
  28. 28.
    Chang RM, Yang H, Fang F, Xu JF, Yang LY. MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase. Hepatology. 2014;60:1251–63.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Gastroenterology and Clinical LaboratoryThe Third People’s Hospital of Nantong CityJiangsuChina
  2. 2.Department of General SurgeryThe Sixth People’s Hospital of Nantong CityJiangsuChina
  3. 3.Department of Clinical Laboratory CenterAffiliated Hospital of Nantong UniversityJiangsuChina

Personalised recommendations